Targets › NIMO
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.
Open in Phaseline: the race on NIMO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Georgetown University | BXCL701 Selective immuno-modulating neddylation inhibitor (NIMA) targeting NEDD8-activating enzyme | NIMA, NIMO | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma | Sep 2027 |
Metastatic Pancreatic Ductal Adenocarcinoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.